JB CHEMICALS: STAY INVESTED
Article Abstract:
JB Chemicals (JBC) has posted a compounded annual growth rate of 20 percent in sales and 25 percent in net profit from 1993-94 to 1997-98. Against the pharma industry's growth of 13 percent in 1997-98, JBC posted a growth rate of 18 percent. It has declared a final dividend of 25 percent along with an interim dividend of 25 percent for 1997-98. JBC manufactures formulations like metronidazole, nifedipine, diclofenac sodium and ranitidine. Exports account for 45 percent of its sales. Formulations contribute 91 percent to its domestic sales. JBC has proposed to issue one bonus share for every one share held. Its Panoli unit, which commenced production in April 1998, has a capacity for 4 crore tablets and 20 lakh ampoules a month. Promoters hold 53 percent stake, financial institutions 17 percent and public 30 percent in the company. JBC has tied with Hafslund Nycomed of Norway, Justesa Imagen SA of Spain and Levasson of Austria to address export markets. (rk) --------------------------------------------------------- Financial Performance of JB Chemicals (Rs in crore) --------------------------------------------------------- Particulars 1997-98 1996-97 --------------------------------------------------------- Sales 189.21 160.22 --------------------------------------------------------- Expenditure 158.93 134.20 --------------------------------------------------------- Gross profit 35.81 30.70 --------------------------------------------------------- Interest 4.65 6.39 --------------------------------------------------------- Depreciation 3.66 3.42 --------------------------------------------------------- Net profit 27.05 19.81 --------------------------------------------------------- Equity 7.26 6.66 --------------------------------------------------------- EPS (Rs) 37.26 29.74 ---------------------------------------------------------
Comment:
Posts compounded annual growth rate of 20% in sales & 25% in net profit from 1993-94 to 1997-98
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
FINE DRUGS AND CHEMICALS
Article Abstract:
Fine Drugs and Chemicals Ltd (FDCL) is mainly involved in the production of ciprofloxacin and salbutamol sulphate. The company has not been able to use its capacity to the fullest extent. It has a capacity of 36 tonnes for Ciprofloxacin but achieved a capacity utilisation of only 48.63 percent in 1997-98. It has incurred a loss of Rs2.14 crore on sales of Rs5.09 crore in 1997- 98 against a loss of Rs0.17 crore on sales of Rs7.33 crore in 1996-97. Vorin Laboratories Ltd has come out with an open offer to acquire a 20 percent stale in FDCL at Rs4 per share after having entered into an agreement to buy a 37.76 percent stake from the promoters of the company. (khr)
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: TATA CHEMICALS NAGARJUNA FERTILIZERS AND CHEMICALS LIMITED. SWC BOARD RECAST, KOMAL WAZIR MADE DIRECTOR
- Abstracts: INDIAN PETROCHEMICALS CORPORATION LIMITED NOVA PETROCHEMICALS LTD. SPCL NON-CONVERTIBLE DEBENTURE
- Abstracts: BRIDGING THE RADIAL GAP INDIA NOW RIDES ON THE WORLD'S NO 1 RADIAL. EUROMEDICA SETS UP SHOP IN INDIA
- Abstracts: JINDAL STRIPS LIMITED: PROFITS THROUGH GROWTH & PRODUCTIVITY INDIAN ACRYLICS LIMITED
- Abstracts: ACC SET TO DILUTE STAKE IN TWO ASSOCIATE FIRMS CHHABRIA'S HOSE PUMP PROJECT GOES TO FALCON MRF SET TO BAIL OUT DUNLOP ON BENGAL GOVT's REQUEST